Evidence of agomelatine's antidepressant efficacy: The key points

International Clinical Psychopharmacology

Volumn 22, Issue SUPPL. 2, 2007, Pages

  Eser, Daniela ^a   Baghai, Thomas C ^a   Möller, Hans Jürgen ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Agomelatine; Antidepressant; Major depression; Melatonin

Indexed keywords

AGOMELATINE; DIAZEPAM; FLUOXETINE; IMIPRAMINE; MELATONIN RECEPTOR; NORADRENALIN UPTAKE INHIBITOR; PAROXETINE; PLACEBO; SEROTONIN UPTAKE INHIBITOR; VENLAFAXINE;

CIRCADIAN RHYTHM; CLINICAL TRIAL; COMPARATIVE STUDY; DEPRESSION; DIZZINESS; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; INSOMNIA; MAJOR DEPRESSION; MYALGIA; NAUSEA; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SEXUAL DYSFUNCTION; SLEEP DISORDER;

ACETAMIDES; ANTI-ANXIETY AGENTS; ANTIDEPRESSIVE AGENTS; CIRCADIAN RHYTHM; DEPRESSIVE DISORDER; HUMANS; RECEPTOR, MELATONIN, MT1; RECEPTOR, MELATONIN, MT2; RECEPTOR, SEROTONIN, 5-HT2C;

EID: 34948858413     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.yic.0000277958.83475.d5     Document Type: Review

References (27)

1. Armstrong SM, McNulty OM, Guardiola-Lemaitre B, Redman JR (1993). Successful use of S20098 and melatonin in an animal model of delayed sleep-phase syndrome (DSPS). Pharmacol Biochem Behav 46:45-49.
2. Barden N, Shink E, Labbe M, Vacher R, Rochford J, Mocaer E (2005). Antidepressant action of agomelatine (S 20098) in a transgenic mouse model. Prog Neuropsychopharmacol Biol Psychiatry 29:908-916.
3. Bourin M, Mocaer E, Porsolt R (2004). Antidepressant-like activity of S 20098 (agomelatine) in the forced swimming test in rodents: involvement of melatonin and serotonin receptors. J Psychiatry Neurosci 29:126-133.
4. Foulkes NS, Borjigin J, Snyder SH, Sassone-Corsi P (1997). Rhythmic transcription: the molecular basis of circadian melatonin synthesis. Trends Neurosci 20:487-492.
5. Gruca P, Przegalisnki E, Mrowiec S, Lason M, Papp M (2004). Evidence for antidepressant- and anxiolytic-like activities of melatonin and agomelatine in animal models. Eur Neuropsychopharmacol 14:S230.
6. Guilleminault C (2005). Sleep as a marker of disrupted circadian rhythms in depression. Eur Neuropsychopharmacol 20:S151.
7. Hamilton M (1986.) The Hamilton rating scale for depression. In: Sartorius N, Ban TA, editors. Assessment of depression. Berlin: Springer; pp. 143-152.
8. Kennedy SH (2005). Sexual function in remitted depressed patients following agomelatine and venlafaxine XR treatment. Eur Neuropsychopharmacol 15:S440.
9. Kennedy SH, Emsley R (2006). Placebo-controlled trial of agomelatine in the treatment of major depressive disorder. Eur Neuropsychopharmacol 16:93-100.
10. Leproult R, Van OA, L'hermite-Baleriaux M, Van CE, Copinschi G (2005). Phase-shifts of 24-h rhythms of hormonal release and body temperature following early evening administration of the melatonin agonist agomelatine in healthy older men. Clin Endocrinol (Oxf) 63:298-304.
11. Lesieur D, Leclerc V, Chavatte P, Marcot C, Renard P, Guardiola-Lemaitre B (1998). Melatonin: a pertinent prototype for therapeutic intervention. Therapie 53:429-437.
12. Loo H, Dalery J, Macher JP, Payen A (2003). Pilot study comparing in blind the therapeutic effect of two doses of agomelatine, melatonin- agonist and selective 5HT2c receptors antagonist, in the treatment of major depressive disorders. Encephale 29:165-171.
13. Loo H, Hale A, D'haenen H (2002). Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT(2C) antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study. Int Clin Psychopharmacol 17:239-247.
14. Millan MJ, Brocco M, Gobert A, Dekeyne A (2005). Anxiolytic properties of agomelatine, an antidepressant with melatoninergic and serotonergic properties: role of 5-HT2C receptor blockade. Psychopharmacology (Berl) 177:448-458.
15. Millan MJ, Gobert A, Lejeune F, Dekeyne A, Newman-Tancredi A, Pasteau V, et al. (2003). The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxytryptamine2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways. J Pharmacol Exp Ther 306:954-964.
16. Montgomery SA, Asberg M (1979). A new depression scale designed to be sensitive to change. Br J Psychiatry 134:382-389.
17. Montgomery SA, Kennedy SH, Burrows GD, Lejoyeux M, Hindmarch I (2004). Absence of discontinuation symptoms with agomelatine and occurrence of discontinuation symptoms with paroxetine: a randomized, double-blind, placebo-controlled discontinuation study. Int Clin Psychopharmacol 19:271-280.
18. Olie JP, Kasper S (2007). Efficacy of agomelatine, a MT1/MT2 receptor agonist with 5-HT2C antagonistic properties, in major depressive disorder. Int J Neuropsychopharmacol 10:661-673.
19. Papp M, Gruca P, Boyer PA, Mocaer E (2003). Effect of agomelatine in the chronic mild stress model of depression in the rat. Neuropsychopharmacology 28:694-703.
20. Quera-Salva MA, Vanier B, Laredo J, Hartley S, Chapotot F, Moulinet C, et al. (2007). Major depressive disorder, sleep EEG and agomelatine: an open-label study. Int J Neuropsychopharmacol 10:691-696.
21. Redman JR, Guardiola-Lemaitre B, Brown M, Delagrange P, Armstrong SM (1995). Dose dependent effects of S-20098, a melatonin agonist, on direction of re-entrainment of rat circadian activity rhythms. Psychopharmacology (Berl) 118:385-390.
22. Rosenbaum JF, Fava M, Hoog SL, Ascroft RC, Krebs WB (1998). Selective serotonin reuptake inhibitor discontinuation syndrome: a randomised clinical trial. Biol Psychiatry 44:77-87.
23. Rosen RC, Lane RM, Menza M (1999). Effects of SSRIs on sexual function: a critical review. J Clin Psychopharmacol 19:67-85.
24. Turek FW, Gillette MU (2004). Melatonin, sleep, and circadian rhythms: rationale for development of specific melatonin agonists. Sleep Med 5: 523-532.
25. Van Reeth O, Olivares E, Turek FW, Granjon L, Mocaer E (1998). Resynchronisation of a diurnal rodent circadian clock accelerated by a melatonin agonist. NeuroReport 9:1901-1905.
26. Van Reeth O, Olivares E, Zhang Y, Zee PC, Mocaer E, Defrance R, et al. (1997). Comparative effects of a melatonin agonist on the circadian system in mice and Syrian hamsters. Brain Res 762:185-194.
27. Wehr TA, Wirz-Justice A (1982). Circadian rhythm mechanisms in affective illness and in antidepressant drug action. Pharmacopsychiatria 15:31-33.